Using sensitive and commercially available radioimmunoassay (RIA), Schultz et al. [129] found that CSF-CART levels were significantly reduced by 30% in DLB patients compared to controls as well as AD patients. This evidence concerns the gene CARTPT and Alzheimer disease.